Silence Therapeutics plc
For the period ended Dec 31, 2025. Filed Mar 5, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 5, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
15. Trade and other payables
| Year ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| $000s | $000s | |
| Trade payables | 4,409 | 3,697 |
| Social security and other taxes | 195 | 244 |
| Accruals and other payables | 5,749 | 8,361 |
| Bonus accrual | 2,964 | 3,445 |
| Corporate income tax payable | 39 | 652 |
| Total trade and other payables | 13,356 | 16,399 |
The Group considers that the carrying amount of trade and other payables approximates their fair value. Bonus accrual and accruals and other payables include accrued severance and other compensation costs that are currently subject to ongoing negotiation.
Included within accruals and other payables at December 31, 2025 and 2024 is $3.0 million and $5.9 million respectively, are expenditures relating to contracted research and development costs.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.